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Abstract
Maintenance therapy in bipolar disorder (BD) is usually required to prevent relapses and improve re-
sidual symptoms. Therefore, in this study, we describe patterns of pharmacological maintenance treat-
ment and identify associated clinical features. This prospective multicentre epidemiological study
recruited a cohort of 739 consecutive out-patients with clinically stable BD. Clinical stability was assessed
at baseline with the Clinical Global Impression scale for BD and depressive symptoms with the Hamilton
Depression Rating Scale. Psychotropic medications were classiﬁed and analysed according to their
mechanism as well as use. Logistic regression models were used to examine the associations between
pharmacological strategies and clinical features. Longer time since last episode [odds ratio (OR) 1.002,
p<0.0001] and family history of psychiatric disorders (OR 1.911, p=0.028) were associated with lithium in
monotherapy ; manic polarity of the most recent episode (OR 3.300, p=0.006) and longer duration of
clinical stability (OR 1.009, p=0.034) with antipsychotic in monotherapy ; depressive polarity of the most
recent episode (OR 2.567, p=0.003) and bipolar II disorder diagnosis (OR 2.278, p=0.008) with anti-
depressant combination ; no ongoing psychiatric co-morbidity (OR 0.230, p=0.004) with lithium and
anticonvulsant ; manic polarity of the most recent episode (OR 3.774, p<0.0001) with lithium and anti-
psychotic ; manic polarity of the most recent episode (OR 2.907, p=0.028) with lithium, anticonvulsant and
antipsychotic. The pharmacological patterns followed published recommendations, except for the ex-
cessive use of antidepressants. This study reveals clinical factors closely related to prescription patterns.
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Introduction
Bipolar disorder (BD) is a major mental health issue
associated with considerable morbidity and mortality
(Hirschfeld & Vornik, 2005). It is characterized by re-
current episodes of mania, hypomania, depression
and mixed states separated by periods of relative
euthymia. Treatments that can stabilize the acute
mood swings in BD are available as is maintenance
treatment. Since BD is a recurrent illness, a long-term
prophylactic treatment is usually recommended
(Suppes et al. 1991) and needed to uphold the initial
therapeutic success. Maintenance therapy is expected
to prevent relapses and reduce threshold symptoms,
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risk of suicide, cycle frequency and mood instability
(APA, 2002). However, psychiatrists do not only as-
sess the therapeutic eﬀect but also the tolerability since
it may be a long-term or even lifelong therapy (Vieta &
Rosa, 2007).
Maintenance therapy is usually required in order to
improve functioning and maintain quality of life since
functional impairment has been related to residual
symptoms (Joﬀe et al. 2004; MacQueen et al. 2000;
Rosa et al. 2009; Wolf & Mu¨ller-Oerlinghausen, 2002).
Patients with subclinical depressive symptoms pres-
ent three to six times more functional impairment in
various domains, such as work, housework and re-
lationships with relatives and friends, than those who
do not have these symptoms (Bonnı´n et al. 2012; Rosa
et al. 2011). Therefore, the importance of identifying
and appropriately treating these symptoms is widely
acknowledged and thus patients can obtain complete
disease remission and thereby improve their clinical
outcomes in both the medium and long term (Perlis
et al. 2006).
Several guidelines are available for the treatment of
BD, covering both management of acute mood epi-
sodes and long-term prophylaxis (APA, 2002; Frye
et al. 2011; Goodwin, 2009 ; Grunze et al. 2010; National
Collaborative Centre for Mental Health, 2006 ; Suppes
et al. 2005; Yatham et al. 2009). Although continuous
eﬀorts have been made to improve the management of
this disease (Murru et al. 2011; Popovic et al. 2011), it is
important to describe the current pharmacological
strategies in clinical practice since BD may be one of
the areas with a wide gap between evidence-based
treatment as recommended by the guidelines and the
actual hands-on clinical approach (Fountoulakis et al.
2005; Vieta & Rosa, 2007). According to the WHO,
usual clinical practice should be assessed by means of
drug utilization studies, which include an analysis of
the prescription and use of medicinal products in the
community with the ﬁnal objective of deﬁning optimal
therapeutic practice (WHO Experts Committee, 1977).
The relevance of subclinical symptoms in long-term
evolution led us to conduct a study in a large sample
of clinically stable BD patients who attended a com-
munity health services setting. The main objectives
were to obtain a cross-sectional estimation of the
presence of subclinical depressive symptoms as re-
ported elsewhere (Vieta et al. 2010a) and to describe
maintenance drug utilization patterns, as reported
herein. Scarce studies have focused on prescription in
community health services. Moreover, most have
centred on treatment patterns during acute phases of
BD (Bellantuono et al. 2007; Montoya et al. 2010) or
studies of mixed samples (Baldessarini et al. 2007;
Ghaemi et al. 2006). Since clinical trials are not suitable
for understanding treatment patterns, our objective
with this naturalistic study was to explore the phar-
macological patterns with relevant clinical features
of BD.
Method
This was a prospective 16-week epidemiological study
of a cohort of consecutive out-patients with clinically
stable BD. The project was called SIN-DEPRES and
was conducted at 88 community-based mental health
services and private clinics across several geographi-
cal regions within Spain from April 2006 to March
2007. The sites involved were selected to make them
representative of prescription patterns across Spain at
the time of the survey by selecting eight consecutive
patients from each centre and including a certain
number of centres according to the population of the
region. Fifteen centres were private psychiatric out-
patient clinics and the rest community-based mental
health centres. To really focus on maintenance treat-
ment, acutely ill patients were excluded. Further de-
tails on the methodology are available elsewhere
(Vieta et al. 2010a, b).
Subjects
The inclusion criteria for patients in this study were:
aged o18 yr ; well-established diagnosis of BD ac-
cording to Diagnostic and Statistical manual of Mental
Disorders criteria (DSM-IV) ; clinical stability for at
least the previous month; presence of at least one
acute aﬀective episode during the 5 yr prior to in-
clusion in the study; given informed consent. Clinical
stability was deﬁned as a score of ‘normal’ or ‘mini-
mal’ on both the depression and mania items of the
Modiﬁed Clinical Global Impressions Scale for bipolar
disorder (CGI-BP-M; Spearing et al. 1997; Vieta et al.
2002). Patients were excluded if no reliable infor-
mation was available at the centre, they presented an
acute aﬀective episode at inclusion or suﬀered from
another serious psychiatric condition, drug addiction,
disorders of the central nervous system, organic brain
disease, head trauma, dementia or an uncontrolled
serious medical condition that could account for sec-
ondary depression (e.g. hypothyroidism). Patients
who had suﬀered a single acute episode of BD and
those participating in clinical trials were excluded.
The study included a sample of 761 BD I and II
patients, 739 of whom were included in the ﬁnal
analysis. Those excluded (n=22) failed to meet the
stability criteria, according to CGI-BP-M, did not
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present with acute episodes within the last 5 yr or
suﬀered from co-morbid medical conditions, such as
hypothyroidism. In total, 733 of them were under
treatment and were assessed in the study.
The study was approved by the Independent
Ethics Committee of one of the participating centres,
Hospital Clinic de Barcelona. All participants were
informed about the study procedures and provided
their written informed consent prior to inclusion.
Procedure
Data were obtained from the patients by means of
a clinical interview and a psychiatric examination.
The interview obtained information about socio-
demographic and clinical data, including history of
psychiatric disorders in ﬁrst-degree relatives, history
of treatments received and the degree of compliance
and satisfaction with the treatment.
In order to determine clinical stability at baseline,
all patients were assessed with the CGI-BP-M, taking
into consideration the last month period (Spearing
et al. 1997; Vieta et al. 2002). The 17-item Hamilton
Depression Rating Scale (HAMD-17; Bobes et al. 2003;
Maier et al. 1988) was also administered to evaluate
the presence and severity of depressive symptoms at
enrolment. In this context ‘mild depression’ at base-
line was deﬁned as a total score between 7 and 17 on
the HAMD-17. Depressive symptoms were likewise
evaluated at enrolment and end of study, using the
Montgomery–Asberg Depression Rating Scale (Lobo
et al. 2002; Montgomery & Asberg, 1979).
The recorded medication included all treatments
being followed by the patient, including all drugs at
prescribed daily doses. The patient’s pharmacological
maintenance treatment at baseline and for 4 months
was encoded according to the Anatomical Therapeutic
Chemical classiﬁcation system (WHO, 2009). In order
to study the pharmacological maintenance patterns of
prescription, the medication prescribed at baseline
was investigated in this study. Descriptive lists of
drug utilization patterns relating to all assessable
patients were produced. Treatment adherence was
also documented according to the investigator’s
judgement based on the doses missed during a stan-
dard week (Weiden et al. 2004). Finally, the investi-
gator recorded the patient’s satisfaction with
treatment on a 5-point Likert scale, ranging from ‘not
at all ’ to ‘extremely satisﬁed’.
Data analysis
The sample size, as described elsewhere (Vieta et al.
2010a, b), was calculated in order to determine the
prevalence of depressive symptoms among clinically
stable BD out-patients.
In order to analyse the relationship between pre-
scription patterns and clinical features of the disorder,
therapeutic strategies were deﬁned a priori, consider-
ing the generic therapeutic classiﬁcation of agents, re-
gardless of their approval for BD treatment : lithium,
anticonvulsant or antipsychotic agents in mono-
therapy, combination of lithium with either anti-
convulsants or antipsychotics or anticonvulsants with
antipsychotics, combination of all three agents and
combination with antidepressants. For this analysis,
pharmacological strategies were classiﬁed as mutually
exclusive. Gabapentin, topiramate and clonazepam
were not considered anticonvulsant treatment pre-
scribed for BD because of lack of evidence base for
their use in this condition.
The clinical variables considered for the analysis
were age, gender, marital status, educational level,
occupational status, living conditions, BD type, clinical
course of rapid cycling or seasonal pattern, past de-
pressive episodes, polarity of the most recent episode
according to DSM-IV-TR, age at ﬁrst episode, number
of episodes per year, time elapsed since the last epi-
sode, duration of the most recent episode, time
elapsed since the last depressive episode, duration of
the most recent depressive episode, duration of clini-
cal stability, live events since last assessment, ongoing
psychiatric co-morbidity, ﬁrst degree relative psychi-
atric history and presence of depressive symptoms.
To analyse the diﬀerences between the described
variables in each pharmacological strategy, analysis of
variance or x2 tests were used, as appropriate, or their
respective non-parametric tests if data did not ﬁt a
normal distribution. Then a logistic regression model
was constructed for each pre-deﬁned strategy to
ascertain which clinical factors were associated with
each strategy. The models were created according to
Hosmer and Lemeshow advice to introduce one
parameter for each 10 observed cases (Hosmer &
Lemeshow, 2000).
Statistic analysis was conducted using the
software Statistical Package for Social Sciences
version 18.0 (SPSS Inc., USA). All p values reported
were two tailed. Statistical signiﬁcance was deﬁned as
p<0.05.
Results
Sample characteristic
Most of the patients were diagnosed with BD type I
(n=537, 72.7%) (Table 1) and 88.2% (n=652) had had
a previous depressive episode. More than half of the
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Table 1. Sociodemographic and clinical characteristics at baseline for all bipolar
disorder (BD) patients
Variable BD total (n=739)
Mean S.D.
Age at enrolment (yr) 46.1 13.7
n %
Gender
Male 295 39.9
Female 438 59.3
Marital status
Married/stable partner 380 51.4
Single 234 31.7
Other situation 120 16.2
Educational level
No education completed 47 1.9
Basic education 279 37.8
High school 386 31.9
University 162 21.9
Occupational status (yes) 291 39.4
Living situation
Alone 105 14.2
With parents 177 24.0
With spouses/children 389 52.6
Residence/sheltered housing or in other situation 54 7.2
Mean S.D.
Time elapsed since last depressive episode (d) 889 1385
Age at ﬁrst episode (yr) 29.7 11.8
Number of episodes per year 1.5 1.1
Time elapsed since last episode (d) 455.4 441.3
Duration of most recent episode (d) 74.1 70.3
Duration of clinical stability (months) 17.0 26.8
n %
BD
Type I 537 72.7
Type II 202 27.3
Clinical course
Rapid cycling 126 17.1
Seasonal pattern 261 35.5
Past depressive episodes (yes) 652 88.2
Polarity of most recent episode
Depressive type (296.5r) 377 51.8
Manic type (296.46) 184 24.9
Hypomanic type (296.40) 127 17.2
Mixed type (296.6r) 46 6.2
Not speciﬁed (297.7) 4 0.5
Life events since last assessment 118 16.0
Ongoing psychiatric co-morbidity
Substance abuse 109 14.7
Panic disorder 50 6.8
Non-speciﬁed anxiety disorders 48 6.5
Family historya
Depressive disorder 254 34.4
BD 139 18.8
Substance abuse 58 7.8
Psychotic disorder–schizophrenia 50 6.8
Presence of mild/subclinical depression (17<HAMDo7) 125 16.9
HAMD, Hamilton Rating Scale for Depression.
a Psychiatric disorders on ﬁrst degree relatives.
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Table 2. Patterns of prescription and clinical features in bipolar disorder patients : qualitative and quantitative variables
Clinical features
Pharmacological strategies n=733
Lithium
monotherapy
n=76
Anticonvulsant
monotherapy
n=45
Antipsychotic
monotherapy
n=26
Antidepressant
combination
n=284
Lithium &
anticonvulsant
n=48
Lithium &
antipsychotic
n=95
Anticonvulsant
& antipsychotic
n=86
Lithium &
anticonvulsant
& Antipsychotic
n=73
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Stats p value
Age at enrolment (yr) 42.0 13.5 47.7 14.0 40.9 11.9 48.7 13.5 47.1 14.8 44.3 13.5 43.4 12.8 45.6 13.0 3.908 <0.0001***
n % n % n % n % n % n % n % n % Stats p value
Gender (woman) 45 6.2 27 3.7 15 2.1 185 25.4 21 2.9 54 7.0 53 7.3 37 5.1 12.709 0.080
Marital status 13.063 0.522
Single 26 3.6 15 2.1 12 1.6 76 10.4 12 1.6 36 4.9 30 4.1 26 3.6
Married/Stable partner 38 5.2 24 3.3 12 1.6 149 20.4 29 4.0 45 6.2 42 5.8 36 4.9
Other situation 11 1.5 6 0.8 2 0.3 58 8.0 7 1.0 13 1.8 13 1.8 11 1.5
Educational level (high school
or above )
48 6.7 28 3.9 12 1.7 144 20.0 26 3.6 51 7.1 39 5.4 46 6.4 10.007 0.188
Occupational status (Yes) 43 6.0 20 2.8 8 1.1 108 15.1 26 3.6 41 5.7 34 4.7 32 4.5 13.610 0.059
Living situation 23.088 0.339
Alone 11 1.5 8 1.1 2 0.3 43 6.0 4 0.6 13 1.8 15 2.1 8 1.1
With parents 20 2.8 8 1.1 11 1.5 56 7.8 11 1.5 31 4.3 19 2.6 21 2.9
With spouse/children 39 5.4 24 3.3 11 1.5 163 22.6 29 4.0 44 6.1 41 5.7 36 4.9
Residence/sheltered housing
or in other situation
5 0.7 5 0.7 1 0.1 20 2.8 2 0.3 4 0.6 8 1.1 8 1.1
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Stats p value
Time elapsed since last
depressive episode (d)
1421.5 1774.3 601.8 695.3 1129.7 1754.8 567.8 1227.6 606.5 655.0 1288.7 2911.0 692.8 780.3 1310.6 1882.8 4.127 <0.0001***
Duration of most recent
depressive episode (d)
98.4 92.8 68.5 61.0 83.8 62.2 95.7 119.9 97.5 75.7 84.8 60.7 59.5 40.7 78.2 62.7 1.748 0.095
Age at ﬁrst episode 27.7 9.3 32.11 13.9 25.5 11.8 31.2 12.2 34.6 12.1 27.4 9.7 28.4 12.2 27.7 9.9 3.985 <0.0001***
Number of episodes per year 1.1 0.8 1.7 0.9 1.1 0.6 1.6 1.3 1.3 0.7 1.3 0.9 1.4 0.9 1.5 0.7 3.175 0.003**
Time elapsed since last
episode (days)
800.2 494.8 517.2 468.0 489.5 491.5 384.2 409.8 483.4 421.2 460.6 462.6 371.3 343.7 380.3 407.4 9.096 <0.0001***
Duration of most recent
episode (days)
72.7 79.1 67.0 61.9 65.5 52.7 80.8 83.0 87.5 77.6 67.2 50.2 64.1 49.3 70.2 55.5 1.137 0.337
Duration of clinical stability
(months)
25.8 16.2 23.0 49.0 29.4 48.4 15.7 30.3 17.8 14.5 15.2 15.2 13.0 16.7 12.6 14.9 3.019 0.004**
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sample (n=377, 51.8%) presented with a depressive
polarity in the most recent episode. Overall, patients
were considered to adhere to the maintenance treat-
ment (n=618, 83.6%). Moreover, most patients
(n=526, 71.2%) were reportedly satisﬁed with their
maintenance regimen. Further details on the descrip-
tion of sociodemographic and clinical data are avail-
able elsewhere (Vieta et al. 2010a).
Patterns of drug treatment
Most of the sample was under an antidepressant as-
sociation strategy (n=284, 38.7%) (Table 2). Anti-
depressant combination patterns and types of
antidepressants were classiﬁed according to the
therapeutic strategies in Table 3. The combination
strategies without antidepressants (n=302, 41.2%)
were more prevalent than monotherapy (n=147,
20.0%). The most prevalent monotherapy was lithium
(n=76, 10.4%). Signiﬁcant diﬀerences were detected
in the clinical features among the pharmacological
strategies regarding age at enrolment (F=3.908,
p<0.0001), BD type (x2=50.573, p<0.0001), past de-
pressive episodes (x2=39.795, p<0.0001), polarity of
the most recent episode (x2=155.486, p<0.0001), on-
going psychiatric co-morbidity (x2=14.481, p=0.043),
family history (x2=18.004, p=0.012), time elapsed
since last depressive episode (F=4.127, p<0.0001), age
at ﬁrst episode (F=3.985, p<0.0001), number of epi-
sodes per year (F=3.175, p=0.003), time elapsed since
last episode (F=9.096, p<0.0001) and duration of
clinical stability (F=3.019, p=0.004; Table 2).
Relationship between prescription patterns
and clinical features of BD
The results of the logistic regressions showed diﬀerent
factors that were signiﬁcantly associated with each
pharmacological strategy (Table 4).
The time elapsed since the last episode [odds ratio
(OR) 1.002, 95% conﬁdence intervals (CI) 1.001–1.002,
p<0.0001] and a family history of psychiatric disorder
(OR 1.911, 95% CI 1.071–3.412, p=0.028) were signiﬁ-
cantly associated with the possibility of following
maintenance treatment with lithium in monotherapy.
Age at enrolment was inversely related to the use
of lithium in monotherapy (OR 0.975, 95% CI
0.954–0.997, p=0.023). No signiﬁcant relationships
were detected in the use of anticonvulsant in mono-
therapy. Manic polarity of the most recent episode (OR
3.300, 95% CI 1.497–9.346, p=0.006) and duration of
clinical stability (OR 1.009, 95% CI 1.001–1.017,
p=0.034) were signiﬁcantly associated with the possi-
bility of following maintenance treatment with an
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antipsychotic in monotherapy. The maintenance
treatment with an antidepressant combination with
other agents was signiﬁcantly associated with de-
pressive polarity of the most recent episode (OR 2.567,
95% CI 1.370–4.809, p=0.003), bipolar II disorder di-
agnoses (OR 2.278, 95% CI 1.239–4.184, p=0.008), and
age at enrolment (OR 1.051, 95% CI 1.020–1.084,
p=0.001). Maintenance treatment with lithium com-
bined with anticonvulsants was signiﬁcantly related
to age at ﬁrst episode (OR 1.091, 95% CI 1.027–1.159,
p=0.005) and inversely related to ongoing psychiatric
co-morbidity (OR 0.230, 95% CI 0.085–0.627, p=0.004).
With regard to the use of lithium combined with an
antipsychotic as a maintenance treatment, a signiﬁcant
association was only shown with manic polarity of the
most recent episode (OR 3.774, 95% CI 2.083–6.849,
p<0.0001). Age at enrolment (OR 0.934, 95% CI
0.898–0.971, p=0.001) was signiﬁcantly related to the
possibility of following maintenance with treatment
with anticonvulsants combined with antipsychotics.
Finally, the use of combined treatment with the three
agents as maintenance therapy was signiﬁcantly as-
sociated with manic polarity of the most recent epi-
sode (OR 2.907, 95% CI 1.124–7.519, p=0.028).
Discussion
In this study several clinical features of bipolar
patients were related to patterns of pharmacological
maintenance strategies. Family history of psychiatric
disorders, longer time since last episode and youth at
the time of enrolment were associated with lithium
monotherapy, manic polarity of the most recent
episode and longer duration of clinical stability
were associated with antipsychotic in monotherapy;
depressive polarity of the most recent episode, BD
type II diagnosis, and older age at the time of enrol-
ment with antidepressant association strategy; older
age at ﬁrst episode and no ongoing psychiatric co-
morbidity with lithium and anticonvulsant strategy;
manic polarity of the most recent episode with lithium
and antipsychotic strategy; youth at enrolment with
anticonvulsant and antipsychotic strategy; and ﬁnally
manic polarity of the most recent episode was as-
sociated with maintenance treatment with lithium,
anticonvulsant and antipsychotic therapy.
Manic polarity of the most recent episode was re-
lated to maintenance treatment with antipsychotics in
monotherapy, in combination with lithium or in com-
bination with lithium and anticonvulsants. These re-
sults are in accordance with current guidelines, which
recommend an approach to bipolar maintenance
treatment based on the concept of predominant po-
larity (Colom et al. 2006; Goodwin, 2009 ; Nivoli et al.
2011b ; Yildiz et al. 2011) or the nature of the preceding
acute episode (Suppes et al. 2005).
On the other hand, depressive polarity of the most
recent episode was associated with antidepressants
combined with maintenance treatment. It is a matter of
debate whether antidepressants should be prescribed
in BD or not, particularly in long-term treatment,
(Nivoli et al. 2011a ; Valentı´ et al. 2011; Vieta et al.
2010b). On one hand, some guidelines do not rec-
ommend their use (APA, 2002; Frye et al. 2011;
Yatham et al. 2009). Despite accepting that adjunctive
antidepressants may be eﬀective in the acute treatment
of BD, it has been suggested that antidepressants do
not appear to provide any additional beneﬁt in long-
term treatment of bipolar depression (Frye et al. 2011).
For this reason, the NICE guidelines limit the use of
Table 3. Antidepressant combination : pattern of pharmacological strategies
Combination (n=284) TCA (n=29) SSRI (n=134) SNRI (n=89) Others (n=32)
n % n % n % n % n %
Lithium 46 16.2 7 2.5 17 6.0 17 6.0 5 1.8
Anticonvulsant 58 20.4 8 2.8 27 9.5 18 6.3 5 1.8
Antipsychotic 18 6.3 2 0.7 10 3.5 4 1.4 2 0.7
Lithium and anticonvulsant 34 12.0 3 1.1 17 6.0 8 2.8 6 2.1
Lithium and antipsychotic 37 13.0 2 0.7 17 6.0 14 4.9 4 1.4
Anticonvulsant and antipsychotic 47 16.5 3 1.1 24 8.5 17 6.0 3 1.1
Lithium, anticonvulsant and
antipsychotics
34 12.0 3 1.1 18 6.3 11 3.9 2 0.7
Others 10 3.5 1 0.4 4 1.4 0 0 5 1.8
TCA, Tricyclic antidepressant ; SSRI, selective serotonin reuptake inhibitor ; SNRI, serotonin–norepinephrine reuptake inhibitors.
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antidepressants at the minimal therapeutic dose in
combination with prophylactic medication (National
Collaborative Centre for Mental Health, 2006). On
the other hand, however, the British Association
for Psychopharmacology does not deny the obvious
fact that prescribing antidepressants in maintenance
Table 4. Logistic regressions corresponding to maintenance pharmacological strategies in bipolar disorder (BD)
b OR 95% CI p value
Strategies
Lithiuma
Family historyb 0.648 1.911 1.071–3.412 0.028*
Time elapsed since last episode 0.002 1.002 1.001–1.002 <0.0001***
Age at enrolment x0.250 0.975 0.954–0.997 0.023*
Antipsychoticc
Manic/mixed polarity of most recent episode 1.302 3.300 1.497–9.346 0.006**
Duration of clinical stability 0.009 1.009 1.001–1.017 0.034*
Antidepressant combinationd
Depressive polarity of most recent episode 0.943 2.567 1.370–4.809 0.003**
Bipolar II disorder 0.822 2.278 1.239–4.184 0.008**
Age at enrolment 0.050 1.051 1.020–1.084 0.001**
Lithium and anticonvulsante
Age at ﬁrst episode 0.087 1.091 1.027–1.159 0.005**
Ongoing psychiatric co-morbidity x1.468 0.230 0.085–0.627 0.004**
Lithium and antipsychoticf
Manic/mixed polarity of most recent episode 1.329 3.774 2.083–6.849 <0.0001***
Anticonvulsant and antipsychoticg
Age at enrolment x0.069 0.934 0.898–0.971 0.001**
Lithium and anticonvulsant and antipsychotich
Manic/mixed polarity of most recent episode 1.066 2.907 1.124–7.519 0.028*
OR, Odds ratio ; CI, conﬁdence interval.
a Variables initially introduced in the model : age at enrolment, number of episodes per year, time elapsed since last episode, BD
type, polarity of most recent episode, past depressive episodes and family history of psychiatric disorder ; Hosmer and
Lemeshow’s test (p=0.850).
b History of depressive disorder, BD, substance abuse, psychotic disorder or schizophrenia on ﬁrst degree relatives.
c Variables initially introduced in the model : duration of clinical stability, and polarity of most recent episode; Hosmer and
Lemeshow’s test (p=0.438).
d Variables initially introduced in the model : age at enrolment, age at ﬁrst episode, time elapsed since last episode, time elapsed
since last depressive episode, number of episodes per year, duration of clinical stability, BD type, polarity of most recent episode,
ongoing psychiatric co-morbidity and family history of psychiatric disorder ; Hosmer and Lemeshow’s test (p=0.205).
e Variables initially introduced in the model : Age at enrolment, age at ﬁrst episode, ongoing psychiatric co-morbidity and family
history of psychiatric disorder ; Hosmer and Lemeshow’s test (p=0.529).
f Variables initially introduced in the model : age at enrolment, age at ﬁrst episode, number of episodes per year, time elapsed
since last episode, duration of clinical stability, BD type, past depressive episodes, polarity of most recent episode, family history
of psychiatric disorder ; Hosmer and Lemeshow’s test (p=0.274).
g Variables initially introduced in the model : age at enrolment, time elapsed since last episode, time elapsed since last depressive
episode, number of episodes per year, duration of clinical stability, BD type, polarity of most recent episode, ongoing psychiatric
co-morbidity ; Hosmer and Lemeshow test (p=0.288).
h Variables initially introduced in the model : age at enrolment, age at ﬁrst episode, time elapsed since last episode, time elapsed
since last depressive episode, BD type, polarity of most recent episode, ongoing psychiatric co-morbidity ; Hosmer and
Lemeshow’s test (p=0.315).
In the model performed for maintenance pharmacological anticonvulsant monotherapy, the variables initially introduced were
number of episodes per year, time elapsed since last episode, duration of clinical stability and ongoing psychiatric co-morbidity.
None was detected as a predictor.
* p<0.05, ** p<0.001, *** p<0.0001.
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treatment is a widely spread clinical practice
(Baldessarini et al. 2007) and suggests that there is not
suﬃcient evidence to recommend the discontinuation
of antidepressants (Goodwin, 2009).
In addition, a signiﬁcant association in the same
pharmacological strategy was found with the BD type
II diagnoses. Given the major burden of the disease
imposed by chronic depressive symptoms and recur-
rent depressive episodes in BD II (Judd et al. 2003; Sole´
et al. 2012), antidepressant prescription may be fore-
seeable (Pacchiarotti et al. 2011).
In the maintenance treatment with lithium in
monotherapy, family history of psychiatric disorder
seemed to be related to this strategy. It is commonly
known that response to a given drug by a patient’s
relative is an important indicator for selecting the
optimal treatment. In the case of lithium, familial clus-
tering of response to treatment reportedly gave a signi-
ﬁcantly better response to lithium prophylaxis among
relatives (Grof et al. 2002; Mendlewicz et al. 1973).
Moreover, youth at the time of enrolment was
associated with lithium in monotherapy as well as
with a combination of anticonvulsants and anti-
psychotics in contrast to the association between old
age at enrolment with the antidepressant combination.
These relationships could be explained as young
patients are presumed not to have suﬀered the dis-
order for long. Therefore, neuroprogression in the
disorder may not have progressed too long and ﬁrst-
line treatments, such as the former, which are initially
prescribed, could still be eﬀective (Yatham et al. 2009)
in contrast to the latter, which is usually prescribed as
a last resort.
Along the same lines, lithium is reported to better
prevent relapseswhen introducedwithin the ﬁrst 10 yr
of illness (Franchini et al. 1999). Thus, patients under
lithium monotherapy may show less severe evolution,
which would not require treatment changes. For this
reason patients under lithium monotherapy may
present with a longer time since last episode.
The combination strategy with lithium and antic-
onvulsants was signiﬁcantly associated with older age
at ﬁrst episode. It could be hypothesized that this may
be due to a delay in the diagnosis in this subsample, a
further progression of the disorder and, consequently,
an ineﬀective monotherapy treatment (Hirschfeld et al.
2003). Moreover, this pharmacological strategy was
inversely associated with psychiatric co-morbidity.
We consider that this relationship results from the
exclusion of anticonvulsants in this study, such as
gabapetin, topiramate and clonazepam, which are
generally used in other psychiatric disorders and in
co-morbid conditions.
With regard to antipsychotics, an association was
found between antipsychotic monotherapy and the
duration of clinical stability, highlighting the suit-
ability to use these drugs in maintenance treatment
(Popovic et al. 2012; Vieta et al. 2011).
The present study has some limitations. Drug in-
dications and prescription patterns vary across coun-
tries. However, a great eﬀort was made to ensure the
representativity of the sample across out-patient
mental health settings in Spain. In fact, similar results
at the prescription pattern were found in the diﬀerent
settings. Nevertheless, the results obtained in our
country may not be fully generalizable to other coun-
tries, where attention and services to the patients may
be diﬀerently distributed. Furthermore, it is important
to bear in mind that this is a cross-sectional study and
does not give a relationship of causality between the
prescription pattern and clinical features. However,
this study on maintenance treatment in BD may shed
some light on this barely unexplored ﬁeld. The results
conﬁrm that, in general, prescription patterns in BD
are in line with published recommendations, except
for the excessive use of antidepressants. This study
also reveals clinical factors that may be closely related
to prescription patterns, for which the evidence-based
treatment may or may not be available, but which
may help to build not only evidence-based but also
experience-based guidelines.
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